15 Feb

BioLife Solutions’ Joint Venture Partner SAVSU Technologies Provides Performance Update on evo® Cold Chain 2.0™ System in ImmunoCellular Therapeutics Phase 3 Glioblastoma Cell Therapy Clinical Trial

ImmunoCellular Therapeutics has successfully deployed SAVSU’s evo® Cold Chain 2.0™ software-as-a-service (SaaS) live cell visibility platform to pack, ship, track and monitor apheresis units from point of collection to cell therapy manufacturing sites. Cellular immunotherapy ICT-107 is a patient-specific autologous dendritic cell immunotherapy under evaluation to treat study patients with glioblastoma in Phase 3 clinical trial NCT02546102.

According to ImmunoCellular’s Marta Schilling, Vice President, Cell Therapy Manufacturing, “We have been extremely pleased with the performance of the evo® Cold Chain 2.0™ system for use in our phase 3 study. The unique uni-directional packout prevents errors in packaging and makes it very simple for our clinical sites to package the starting apheresis product for shipment to our manufacturing facilities. Validation of tight temperature stability in every shipment is critical, and we have not experienced any temperature or packaging deviations since switching to evo®. It is clear that an enormous amount of thought and testing went in to the design of the evo® system.”

For more information, please read the press release.

Comments are closed.